Healthcare / Medical DevicesNasdaqGM
$8.63
+0.22 (+2.62%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-27.1M · quality 79.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$326M
P/E
N/A
•EV/EBITDA
N/A
•ROE
13.6%
↑Gross Margin
50.6%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
+15.9%
FCF CAGR
—
FCF margin
-43.9%
FCF / Net income
-1.26x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $56.2M · net income $19.5M · FCF $-24.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $56.2M | $56.2M | $47.7M | $50.2M | $46.9M | $42.2M | $26.9M |
| Net Income | $19.5M | $19.5M | $-72.2M | $-36.4M | $-33.6M | $-22.2M | $-12.8M |
| EBITDA | $-21.2M | $-21.2M | $-25.3M | $-34.0M | $-31.8M | $-21.1M | $-5.0M |
| EPS | — | — | -2.12 | -1.13 | -1.07 | -0.79 | -2.35 |
| Gross Margin | 50.6% | 50.6% | 51.3% | 50.4% | 55.5% | 55.0% | 55.5% |
| Operating Margin | -45.7% | -45.7% | -62.7% | -84.9% | -75.5% | -52.3% | -21.6% |
| Net Margin | 34.7% | 34.7% | -151.2% | -72.5% | -71.6% | -52.5% | -47.7% |
| Balance Sheet | |||||||
| Debt/Equity | 0.03 | 0.03 | 0.04 | 0.04 | 0.10 | 0.07 | 0.10 |
| Current Ratio | 3.58 | 3.58 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-24.6M | $-24.6M | $-30.8M | $-27.1M | $-23.0M | $-29.8M | $4.1M |
| Returns | |||||||
| ROE | 13.6% | 13.6% | -63.0% | -22.0% | -17.6% | -10.3% | -9.2% |
| Valuation | |||||||
| P/B | 2.18 | 2.18 | 0.68 | 1.67 | 1.21 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 17.7% | 17.7% | -4.9% | 7.2% | — | 56.9% | — |
| EPS Growth | — | — | -87.6% | -5.6% | — | 66.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+51.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.12 → n/d
Residual
+51.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.